Literature DB >> 30688388

Divergence and heterogeneity of neoplastic PD-L1 expression: Two autopsy case reports of intravascular large B-cell lymphoma.

Ayako Sakakibara1, Yuichiro Inagaki2, Eiki Imaoka3, Yu Sakai4, Masafumi Ito5, Eri Ishikawa1, Satoko Shimada1, Kazuyuki Shimada6, Yuka Suzuki1, Shigeo Nakamura1, Akira Satou7, Kei Kohno1.   

Abstract

Intravascular large B-cell lymphoma (IVLBCL) is a distinct disease, but the neoplastic PD-L1 expression on tumor cells may vary among cases. We evaluated 10 IVLBCL autopsy cases for neoplastic PD-L1 expression, and had positive results in two cases. In one case, neoplastic PD-L1 expression (SP142, 28-8, and E1J2J clones) was dependent on the organ and anatomical site (capillaries vs. vessels) of the tumor tissue. Neoplastic PD-L1 expression was found in tumor cells located in capillaries in the central nervous system, pituitary gland, kidneys, lung, and gastrointestinal tract; sinuses/sinusoids of the spleen, liver, bone marrow, and lymph nodes; and an extravascular location. However, this expression was not detected in tumor cells located in the adrenal gland, thyroid gland, pancreas, ovaries, uterus, pleura, and small or larger-sized vessels of the lung. The other case showed constant neoplastic PD-L1 expression on the tumor cells, and in addition to the affected organs, capillaries, and vessels with two anti-PD-L1 antibodies (28-8 and E1J2J, but not SP142). The divergence and heterogeneity of neoplastic PD-L1 expression were clearly demonstrated in our cases. To the best of our knowledge, this is the first description of divergent neoplastic PD-L1 expression among the affected organs and anatomical sites in IVLBCL.
© 2019 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  autopsy; intravascular large B-cell lymphoma; neoplastic PD-L1 expression divergence or heterogeneity

Mesh:

Substances:

Year:  2019        PMID: 30688388     DOI: 10.1111/pin.12757

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  5 in total

Review 1.  Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.

Authors:  Taishi Takahara; Akira Satou; Toyonori Tsuzuki; Shigeo Nakamura
Journal:  Diagnostics (Basel)       Date:  2022-06-20

2.  Case Report: Intravascular Large B-Cell Lymphoma: A Clinicopathologic Study of Four Cases With Review of Additional 331 Cases in the Literature.

Authors:  Yingying Han; Qingjiao Li; Dan Wang; Lushan Peng; Tao Huang; Chunlin Ou; Keda Yang; Junpu Wang
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

3.  PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.

Authors:  Yuka Suzuki; Kei Kohno; Kosei Matsue; Ayako Sakakibara; Eri Ishikawa; Satoko Shimada; Kazuyuki Shimada; Seiyo Mabuchi; Taishi Takahara; Seiichi Kato; Shigeo Nakamura; Akira Satou
Journal:  Cancer Med       Date:  2020-05-05       Impact factor: 4.452

Review 4.  Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.

Authors:  Ayako Sakakibara; Kei Kohno; Eri Ishikawa; Yuka Suzuki; Yuta Tsuyuki; Satoko Shimada; Kazuyuki Shimada; Akira Satou; Taishi Takahara; Akiko Ohashi; Emiko Takahashi; Seiichi Kato; Shigeo Nakamura; Naoko Asano
Journal:  J Clin Exp Hematop       Date:  2021-09-10

5.  Post-mortem diagnosis of intravascular large B-cell lymphoma.

Authors:  Aniello Maiese; Raffaele La Russa; Alessandra De Matteis; Paola Frati; Vittorio Fineschi
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.